荆花胃康对糜烂性胃炎患者胃黏膜环氧合酶的影响

The changes of cyclooxygenase in patients with erosive gastritis treated with Jinghuaweikang

目的观察荆花胃康治疗糜烂性胃炎的疗效及其作用机制。方法糜烂性胃炎患者共40例,随机分为荆花胃康组和硫糖铝组,疗程均为28 d。观察治疗前后胃黏膜炎症分级、COX-1及COX-2的表达变化。结果两种药物均可显著减轻胃黏膜的慢性活动性炎症,两药间疗效无显著性差异(P>0.05)。荆花胃康治疗后慢性活动性胃炎患者胃黏膜COX-1表达无变化(P>0.05),COX-2表达显著降低(P<0.05)。结论荆花胃康治疗糜烂性胃炎有较好的疗效,其机制与降低胃黏膜COX-2表达有关。

Objective To investigate the therapeutic effect of Jinghuaweikang on patients with erosive gastritis and determine its machanism. Methods Forty patients with erosive gastritis were randomly divided into two groups： Jinghuaweikang group and Sucralfate group. The therapeutic duration was 28 days. The changes of inflammatory grades, expressions of COX-1 and COX-2 in gastric mucosa were investigated. Results Both Jinghuaweikang and Sucralfate could reduce the inflammatory grades of gastric mucosa with similar effects, and there was no significant change for the expression of COX-1 after treatment （P 〉 0.05 ）, meanwhile COX-2 expression was decreased （P 〈 0.05 ）. Conclusion Jinghuaweikang is effective in patients with erosive gastritis. The machanism correlates with the down-regulation of COX-2 expression.